Zydus Lifesciences has introduced Tishtha, India’s first biosimilar of Nivolumab, a pioneering immunotherapy drug for cancer treatment. Priced at ₹28,950 for 100 mg and ₹13,950 for 40 mg, the launch aims to make advanced oncology therapies more affordable and accessible to patients across India.
Show moreStay Ahead – Explore Now! HCLTech Deepens AI Partnership with Team Global Express to Transform Logistics
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
